SRTA Strata Critical Medical, Inc.

Joby Aviation, Inc. (NYSE:JOBY) shares edged higher Friday after the company filed a prospectus supplement covering up to 2.42 million shares for potential resale by Strata Critical Inc. Investors are also evaluating Joby’s autonomous cross-country flight tour. The stock reached a new 52-week low of $6.25 on Thursday. Resale Shares Stem From Blade Acquisition Joby will not receive proceeds from any resale, as it is not selling shares under the prospectus. Strata Critical may sell the shares thro

Strata Critical Medical, Inc. (SRTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The mean of analysts' price targets for Strata Critical Medical, Inc. (SRTA) points to a 47.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Clinical revenue surged 22.6% (including acquisitions) sequentially as acquisitions bolster transplant services.

Immersion Investment Partners, an investment management company, released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Immersion Investment Partners returned 39.1% in the second quarter, surpassing the Russell 2000 Index’s 21.5% gain. The market started valuing their non-AI investments more rationally in the quarter, focusing on strong management, revenue […]

Strata Critical Medical, Inc. (SRTA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Moby summary of Strata Critical Medical, Inc.'s Q2 2026 earnings call

Strata Critical Medical Inc (SRTA) boosts 2026 outlook after record Q2 performance driven by transplant services and strategic acquisitions.

The consensus price target hints at a 60% upside potential for Strata Critical Medical, Inc. (SRTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.